Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 297

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 297
---
      (101,122)      (26.2)  
  Selling expenses                                                                         (152,004)      (38.6)      (150,717)      (39.1)  
  Administrative expenses                                                                   (16,923)       (4.3)       (16,821)       (4.4)  
  Research and development expenses                                                         (13,782)       (3.5)        (9,286)       (2.4)  
  Other net operating income                                                                   5,155         1.3          5,027         1.3  
  Taxation charge                                                                           (15,995)       (4.1)       (17,022)       (4.4)  
  Profit for the year                                                                         92,929        23.6         95,463        24.8  
  Equity in earnings of equity investee attributable to our company (1)                       46,469        11.8         47,295        12.3  

  (1)      Equity in earnings of equity investee attributable to our company is presented under US GAAP. The amounts for the years ended December 31, 2023 and 2024 include elimination of unrealized profit...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Shanghai Hutchison Pharmaceuticals’ revenue increased by 2.1% to $393.5 million for the year ended December 31, 2024 from $385.5 million for the year ended December 31, 2023, primarily due to an increase in sales of She Xiang Bao Xin pills, a vasodilator used in the treatment of heart conditions. Sales of She Xiang Bao Xin pills increased by 3.9% to $362.3 million for the year ended December 31, 2024 from $348.6 million for the year ended December 31, 2023.

Cost of sales increased by 5.8% to $107.0 million for the year ended December 31, 2024 from $101.1 million for the year December 31, 2023, primarily due to higher sales of She Xiang Bao Xin pills. Shanghai Hutchison Pharmaceuticals’ revenue increased at a lower rate than the cost of sales mainly due to the impact of gradual price adjustment from volume-based procurement.

Selling